Data protection Impressum

Technology Park

Neuchâtel is strengthening its position in the semiconductor industry with a CHF 3 million investment in CSEM’s MEMS manufacturing line.

Neuchâtel launches its own “Chip Act” with CHF 3 million investment in CSEM

4 March 2025

The Swiss Institute of Bioinformatics has inaugurated the Centre for Pathogen Bioinformatics in Bern, a state-of-the-art facility dedicated to strengthening genomic surveillance of infectious diseases.

The Centre for Pathogen Bioinformatics was inaugurated in Bern

4 February 2025

EPFL Innovation Park biotech company AB2 Bio has signed an option and licensing agreement with Japan-based Nippon Shinyaku to advance Tadekinig alfa, a novel treatment for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome. The deal includes up to USD 36 million in early payments and milestone-based funding of up to USD 650 million.

AB2 Bio secures USD 650 million partnership with Nippon Shinyaku for rare disease therapy

27 January 2025

CSEM, in collaboration with Thales Alenia Space and Lisi Aerospace Additive Manufacturing, has created an innovative 3D-printed pipe segment for advanced thermal management systems in satellites.

CSEM develops a 3D-printed thermal control system for satellites

22 January 2025

Geneva-based Cerret has launched its discreet safety bracelet, merging luxury design with advanced emergency technology. Global demand is growing rapidly, with over 150 units already shipped worldwide and 400 pre-orders in progress.

Geneva’s Cerret rethinks safety with its innovative luxury bracelet

21 January 2025

The Métiers du Temps | Time Arts (MTTA) project, a cutting-edge watchmaking initiative in Neuchâtel, has received national recognition from the Swiss Confederation. The project, led by Microcity, has been awarded CHF 1.6 million over four years (2025-2028) by the Federal Department of Economic Affairs, Education and Research (EAER).

Neuchâtel’s MTTA recognized as a nationally significant research infrastructure

13 January 2025

Vandria, a Lausanne-based biotech pioneer in mitochondrial therapeutics, has dosed the first participants in a Phase 1 clinical trial for its lead compound, VNA-318, marking a critical step toward addressing neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Vandria begins clinical trials for Alzheimer’s drug VNA-318

7 January 2025

Lausanne-based start-up Precisia Care has raised CHF 1 million in funding to enhance hospital resource management and improve patient safety through its AI-powered, real-time clinical data solutions.

Precisia Care secures CHF 1 million to optimize hospital resource management with AI

6 January 2025

Romande Energie has partnered with Fribourg-based start-up YORD to drive energy efficiency in building heating systems, supporting Switzerland’s decarbonization goals.

Romande Energie invests in YORD to boost building energy efficiency

2 December 2024

EPFL and the canton of Fribourg have announced the creation of six additional research chairs at EPFL's Fribourg campus, strengthening its role as a hub for sustainable innovation in the built environment.

EPFL’s Fribourg campus expands with six new research chairs by 2030

2 December 2024

1 2 3 4 5 6 7 … 20